Bristol-Myers Squibb have recently announced the failure of the drug Opdivo® (nivolumab) to show a clinically significant effect in the treatment of small-cell lung cancer.
Browsing: Disease Area > Lung
In this round up we provide you with the biggest headlines and highlights from the IASLC World Conference on Lung Cancer (WCLC) the world’s largest meeting dedicated to lung cancer and other thoracic malignancies.
A Phase III trial involving the combination of immunotherapy and chemotherapy has seen significantly improved overall survival and progression-free survival in extensive-stage small-cell lung cancer patients.
In this review article from Future Oncology find out about the PACIFIC trial design as well as the future of immunotherapy combinations and biomarkers beyond PD-L1.
Scientists have discovered a key molecular player in lung cancer, which could be used to tackle the disease.
The China National Drug Administration have granted rapid approval of Alecensa® as a monotherapy treatment for patients with ALK-positive, advanced non-small cell lung cancer.
Immune checkpoint inhibitors revolutionized the treatment of non-small-cell lung cancer, although their costs are a limitation; find out more in this article from Immunotherapy.
Findings demonstrate the potential of T2-weighted MRI in dual imaging and radiotherapy systems that aim to image and treat tumors simultaneously.
Lung cancer risk assessment could be improved over existing guidelines by a four-protein biomarker blood test.
A team of researchers have developed the first comprehensive atlas of lung tumor cells.